Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

Journal of Clinical Oncology

Volumn 23, Issue 25, 2005, Pages 5900-5909

  Eberhard, David A ^a   Johnson, Bruce E ^a   Amler, Lukas C ^a   Goddard, Audrey D ^a   Heldens, Sherry L ^a   Herbst, Roy S ^a   Ince, William L ^a   Jänne, Pasi A ^a   Januario, Thomas ^a   Johnson, David H ^a   Klein, Pam ^a   Miller, Vincent A ^a   Ostland, Michael A ^a   Ramies, David A ^a   Sebisanovic, Dragan ^a   Stinson, Jeremy A ^a   Zhang, Yu R ^a   Seshagiri, Somasekar ^a   Hillan, Kenneth J ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PACLITAXEL; PLACEBO; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG POTENTIATION; EXON; GENE; GENE MUTATION; HUMAN; KRAS GENE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MONOTHERAPY; MUTATIONAL ANALYSIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; SEQUENCE ANALYSIS; TREATMENT OUTCOME; ADULT; AGED; FEMALE; GENETICS; LUNG TUMOR; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NUCLEOTIDE SEQUENCE; ONCOGENE RAS; PREDICTION AND FORECASTING; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, RAS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PLACEBOS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 24944497744     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.857     Document Type: Article

References (31)

1. Parkin DM, Bray FI, Devasa SS: Cancer burden in the year 2000: The global picture. Eur J Cancer 37:S4-S66, 2001
2. Sanchez-Cespedes M, Ahrendt SA, Piantadosi S, et al: Chromosomal alterations in lung adenocarcinoma from smokers and non-smokers. Cancer Res 61:1309-1313, 2001
3. Ahrendt SA, Decker PA, Alawi EA, et al: Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 92:1525-1530, 2001
4. Grossi F, Loprevite M, Chiaramondia M, et al: Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers. Eur J Cancer 39:1242-1250, 2003
5. Broermann P, Junker K, Brandt BH, et al: Trimodality treatment in stage III non small cell lung carcinoma: Prognostic impact of K-ras mutations after neoadjuvant therapy. Cancer 94: 2055-2062, 2002
6. Huncharek M, Muscat J, Geschwind JF: K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: A combined analysis of 881 cases. Carcinogen 20:1507-1510, 1999
7. Nelson HH, Christiani DC, Mark EJ, et al: Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J Nat Can Inst 91:2032-2038, 1999
8. Rajagopalan H, Bardelli A, Lengauer C, et al: Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418:934, 2002
9. Keller SM, Vangel MG, Adak S, et al: The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer. Lung Cancer 37:303-309, 2002
10. Schiller JH, Adak S, Feins RH, et al: Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: A laboratory ancillary study on an Eastern Cooperative Oncology Group prospective randomized trial of postoperative adjuvant therapy. J Clin Oncol 19:448-457, 2001
11. Graziano SL, Gamble GP, Newman NB, et al: Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol 17:668-675, 1999
12. Akita RW, Sliwkowski MX: Preclinical studies with erlotinib (Tarceva). Semin Oncol 30:16-24, 2003
13. Perez-Soler R, Chachoua A, Hammond LA, et al: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22:3238-3247, 2004
14. Sandler A: Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinib. Oncology (Huntington) 17:17-22, 2003
15. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237-2246, 2003
16. Miller VA, Kris MG, Shah N, et al: Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22, 2004
17. Giaccone G, Herbst RS, Manegold C, et al: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1. J Clin Oncol 22:777-784, 2004
18. Herbst RS, Giaccone G, Schiller JH, et al: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 22:785-794, 2004
19. Herbst RS, Prager D, Hermann R, et al: TRIBUTE: A phase III trial of erlotinib HCI (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 22:617, 2004 (abstr 7011)
20. Baselga J: Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: How do we go from INTACT to impact? J Clin Oncol 22:759-761, 2004
21. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
22. Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
23. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306-13311, 2004
24. Johnson BE, Lucca J, Rabin MS, et al: Preliminary results from a phase II study of the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in patients >70 years of age with previously untreated advanced non-small cell lung carcinoma. J Clin Oncol 22:633, 2004 (abstr 7080)
25. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137, 2001
26. Bianco R, Shin I, Ritter CA, et al: Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22: 2812-2822, 2003
27. She Q-B, Solit Basso A, et al: Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clin Cancer Res 9:4340-4346, 2003
28. Suzuki T, Nakagawa T, Endo H, et al: The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene status. Lung Cancer 42:35-41, 2003
29. Sugio K, Ishida T, Yokoyama H, et al: Ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res 52:2903-2906, 1992
30. 29A. Herbst RS, Prager D, Hermann R, et al: TRIBUTE: A phase III trial of erlotinib HCI (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23: 10.1200/JCO.2005.02.840
31. Shepherd FA, Pereira J, Ciuleanu TE, et al: A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. J Clin Oncol 22:18, 2004 (abstr 7022)